Consistent with the previously reported anti-tumor effect of immune checkpoint blockers combined with CD73 targeted drugs, the use of AB680 combined with PD-1 blocking in vitro can overcome the inhibitory effect of adenosine on human T cells and enhance the anti-tumor activity of drugs and the anti-tumor effect in vivo (88). This evidence concerns the gene PDCD1 and neoplasm.